米利诺尼促进了心脏骤停后的复苏,并减轻了复苏后的心肌功能障碍
James T Niemann1, Daniel Garner, Emad Khaleeli
1Harbor-UCLA Medical Center, Department of Emergency Medicine and the David Geffen UCLA School of Medicine, Los Angeles, Calif, USA. jniemann@emedharbor.edu
Circulation
|November 26, 2003
概括
米利诺治疗改善了心脏骤停后的结果,因为它减少了复苏后的左心室功能障碍. 这种固酶III抑制剂促进了猪的恢复,并防止了猪的复苏后并发症.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 左心室 (LV) 功能障碍和心肺复苏后心脏指数低与多器官衰竭的早期死亡率有关.
- 对复苏后LV功能障碍的有效治疗方法仍然难以捉摸.
研究的目的:
- 调查选择性固醇酶III抑制剂milrinone在心脏骤停后成功复苏后治疗LV功能障碍的疗效.
主要方法:
- 32只猪接受了电气诱导的心室动 (VF) 5分钟.
- 在CPR过程中,动物接受了盐水 (对照) 或米利诺.
- 血液动力学参数,包括中风体积和LV dp/dt,在复苏后进行评估.
主要成果:
- 米利诺尼治疗显著降低了阻燃性无脉动电活动后除 (0/16对比6/16对照动物).
- 在复苏后30分钟和60分钟,米利诺尼组中,中风体积和LV dp/dt显著更高.
- 没有观察到心率的显著差异;在milrinone组中,周围血管阻力较低.
结论:
- 米利诺尼促进了长期心室动的成功复苏.
- 在复苏后,米利诺尼减轻左心室功能障碍.
- 米利诺尼治疗不会恶化心肌氧氧气需求的关键决定因素.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


